Crizotinib 250mg (Crizotinib)

Contact us for more information
Wishlist Compare
Brand nameCrizalkInternational trade nameXalkoriActive substanceCrizotinibStrength250mgCategoryAnti Cancer

Description of Crizalk 250mg (Crizotinib 250mg)

Crizalk 250mg (Crizotinib 250mg) belongs to type of tyrosine kinase inhibitor. Kinases are enzymes which are included in many functions, involving cell development and reproduction.

Crizalk 250mg (Crizotinib 250mg) is made specifically for the treatment of a type of lung cancer in which ALK is overactive due to an abnormality in the ALK gene.

Crizalk 250mg (Crizotinib 250mg) is a prescription medicine which is used under the supervision of medical practioner

Medical use /Indication of Crizalk 250mg (Crizotinib 250mg)

Crizalk 250mg (Crizotinib 250mg) is indicated for the therapy of patients having metastatic non-small cell lung cancer.

Mechanism of Action Crizalk 250mg (Crizotinib 250mg)

Particularly, crizotinibprevents anaplastic lymphoma kinase (ALK), hepatocyte growth factor receptor (HGFR, c-MET), and Recepteurd'OrigineNantais (RON).

Malformations in the ALK gene result by mutations or translocations may leads expression of oncogenic fusion proteins. somepatients with NSCLC, they have the EML4-ALK gene.

Crizotinib inhibits ALK tyrosine kinase which essentially results in decreasedproliferation of cells which carry the genetic mutation and tumour survivability.

ADME of Crizalk 250mg (Crizotinib 250mg)   

Maximum serum concentration is 4 to 6 hours and bioavailability were 43%.

Volume of distribution is 1772L and plasma protein bounding is 91%

Crizalk 250mg (Crizotinib 250mg)  metabolised by CYP3A4 and CYP3A5

Crizalk 250mg (Crizotinib 250mg)  is eliminated via feces 63% and 22% via urine and half -life is 42 hours

Side effects of Crizalk 250mg (Crizotinib 250mg)

Crizalk 250mg (Crizotinib 250mg)  is caused some side effects as follows :

  • Infection increased
  • Breathlessness
  • Eyesight changes
  • Bowel changes
  • Feeling sick
  • Swelling of hands and feet’s
  • Decreased appetite
  • Fatigue
  • Liver changes
  • Skin rash
  • bradycardia.

Precautions of Crizalk 250mg (Crizotinib 250mg)

Before using Crizalk 250mg (Crizotinib 250mg)  in some condition, consult with doctor.

Hepatotoxicity causes while treatment with Crizalk 250mg (Crizotinib 250mg) 

while treatment with Crizalk 250mg (Crizotinib 250mg)  will causes Interstitial lung disease/pneumonitis.

QT interval prolongation


Severe visual loss

Embryo-fetal toxicity:

Based on mechanism action the medicine will cause risk to foetus

Drug interaction of Crizalk 250mg (Crizotinib 250mg)

Crizalk 250mg (Crizotinib 250mg) Combination with strong or moderate CYP3A4 inhibitors will increase Crizalk plasma concentration

Crizalk200mg concomitant use with strong CYP3A inducers will decrease Crizalk plasma concentration

Crizalk 250mg (Crizotinib 250mg) Interaction with CYP3A substrates will increase plasma concentration of CYP3A substrates
Do not use combination with bradycardia causing medicines.

Pregnancy of Crizalk 250mg (Crizotinib 250mg)

Depends on the studies of animal and mechanism of action, Crizalk 250mg (Crizotinib 250mg) will cause fetal harm when given to pregnant women.

Inform the female not to become pregnant while on treatment with Crizalk 250mg (Crizotinib 250mg)

Lactation of Crizalk 250mg (Crizotinib 250mg)

During treatment with Crizalk 250mg (Crizotinib 250mg), advise the women not to breastfed to infants

Dosage of Crizalk 250mg (Crizotinib 250mg)

Crizalk 200 mg taken orally twice daily for First dose reduction

Crizalk 200 mg taken orally once daily for Second dose reduction

Permanently discontinue if unable to tolerate Crizalk 200 mg taken orally once daily.

Dosage and administration :

Select patients for the treatment with Crizalk based on ALK or ROS1 presences in tumor specimens

The usual dosage of Crizalk is 200mg orally twice in a day

Administer the Crizalk dose with or without food, until disease progression.

Storage of Crizalk 250mg (Crizotinib 250mg)

Store at 20℃ to 25℃ in the original container, avoid freeze

Before to administration keep at room temperature

Crizalk 250mg (Crizotinib 250mg)  protect from direct light and heat.

Missed dose of Crizalk 250mg (Crizotinib 250mg)

If the patient vomits after taking a dose of Crizalk 250mg (Crizotinib 250mg) or missed to take a dose, then should not to take an extra dose, but to take the next dose at the regular time, skip the missed dose.

Brand name:
International trade name:
Active substance:
Anti Cancer
60 capsules
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India